Umlaut.bio

Umlaut.bio is a pioneering biotechnology company focused on developing first-in-class biological therapies for cancer and inflammatory diseases. Small molecules will be developed to inhibit key steps in tRNA modification synthesis, thereby preventing the hyperactivation of multiple signaling pathways on a large scale. This characteristic of uncontrolled cell proliferation in cancer and autoimmune diseases cannot be addressed by chemotherapy or targeting individual proteins. Making this new layer of regulation druggable holds promise to address the shortcomings of current cancer and autoimmune treatments.